Accelerated Aging And Healthcare Reforms Will Spark Immunotherapy Breakthroughs
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
13 Aug 25
Updated
21 Aug 25
AnalystHighTarget's Fair Value
€2.60
59.8% undervalued intrinsic discount21 Aug
€1.05
1Y
0.1%7D
2.5%